RE: Moneyweek17 Nov 2025 20:41
"On 6 August 2025, the Company granted 358,772 options over new ordinary shares with an exercise price of 11 pence per share ("New Options") to Sofia Kolyda, a Director of the Company. The New Options expire on 6 August 2035 with 269,079 of the New Options vesting on the first anniversary of the options being granted (being 6 August 2026) and the balance (comprising 89,693 New Options) vesting once the Company signs a commercial agreement with a partner providing revenues equal to or greater than £100k per annum for products containing SweetBiotix."
Not a lot riding on that!